DELEURAN, Mette et al. Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use. Acta Dermato-Venereologica, [S. l.], v. 101, n. 7, p. adv00504, 2021. DOI: 10.2340/00015555-3848. Disponível em: https://medicaljournalssweden.se/actadv/article/view/133. Acesso em: 25 nov. 2024.